CD4 T-cell Immunotherapy Shows Activity in Solid Tumors

For the first time, treatment with genetically engineered T-cells has used CD4 T-cells instead of the CD8 T-cells, which are used in the chimeric antigen receptor (CAR) T-cell approach. Early data suggest that this CD4 T-cell approach has activity against solid tumors, whereas the CAR T-cell approach so far has achieved dramatic success in hematologic malignancies.

http://www.medscape.com/viewarticle/862095

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *